1. The Prevalence of Sentinel Lymph Node Positivity and Implications for the Utility of Frozen Section Diagnosis Following Neoadjuvant Systemic Therapy in Patients with Clinically Node-Negative HER2-Positive or Triple-Negative Breast Cancer.
- Author
-
Wanis KN, Goetz L, So A, Glencer AC, Sun SX, Teshome M, Resetkova E, Hwang RF, Hunt KK, Candelaria RP, Huo L, and Singh P
- Subjects
- Humans, Female, Middle Aged, Aged, Adult, Follow-Up Studies, Prevalence, Prognosis, Breast Neoplasms pathology, Breast Neoplasms metabolism, Breast Neoplasms therapy, Breast Neoplasms drug therapy, Breast Neoplasms surgery, Lymphatic Metastasis, Aged, 80 and over, Lymph Node Excision, Neoadjuvant Therapy, Frozen Sections, Receptor, ErbB-2 metabolism, Triple Negative Breast Neoplasms pathology, Triple Negative Breast Neoplasms metabolism, Triple Negative Breast Neoplasms therapy, Triple Negative Breast Neoplasms surgery, Sentinel Lymph Node pathology, Sentinel Lymph Node surgery, Sentinel Lymph Node metabolism, Sentinel Lymph Node Biopsy
- Abstract
Background: Axillary dissection is the standard of care for patients with positive sentinel lymph nodes (SLNs) following neoadjuvant systemic therapy. Frozen section can provide intraoperative information regarding the need for axillary dissection during the index operation. However, there are limited data on the utility of frozen section in patients with clinically node-negative (cN0) HER2-positive or triple-negative breast cancer., Methods: We conducted a single-institution observational cohort study including patients with non-inflammatory, cN0, HER2-positive or triple-negative breast cancer treated with neoadjuvant systemic therapy between 2015 and 2019. We estimated the prevalence of SLN positivity and the diagnostic test characteristics of SLN frozen section., Results: Overall, 662 patients were eligible for inclusion, and 44 patients had one or more positive SLNs (prevalence: 6.6%, 95% confidence interval [CI] 4.9-8.8). There were 490 (74.0%) patients who had intraoperative frozen section, and 19 (3.9%) tested positive among 33 (6.7%) with positive final pathology. Frozen section sensitivity was 57.6% (95% CI 39.2-74.5), specificity was 100% (95% CI 99.2-100), positive predictive value was 100% (95% CI 82.4-100), and negative predictive value was 97.0% (95% CI 95.1-98.4). The sensitivity of frozen section for detection of micrometastases or isolated tumor cells was 35.3% (95% CI 14.2-61.7)., Conclusion: In patients with cN0 HER2-positive or triple-negative breast cancer who have been treated with neoadjuvant therapy, positive SLNs are uncommon and frozen section sensitivity is modest. Decisions to defer SLN evaluation to final pathology, which may be reasonable in many settings, can be informed, in part, by these findings., (© 2024. Society of Surgical Oncology.)
- Published
- 2024
- Full Text
- View/download PDF